Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
Data from the comprehensive clinical program show AMG 334 (erenumab) is safe and effective at preventing migraine in patients with 4 or more migraine days per month. AMG 334 (erenumab) significantly reduced monthly migraine days in patients with the highest need, suffering from chronic migraine with acute medication overuse - â? Migraine patients urgently need new treatment options, as currently available preventive therapies are often discontinued due to side effects or lack of effectiveness The digital press release with multimedia content can be accessed here: - Novartis today announced that it will present 19 scientific abstracts at the 59th Annual Scientific Meeting of the American Headache Society (June 8-11, 2017, Boston, USA). This includes a new analysis from a pivotal study highlighting the efficacy of AMG 334 (erenumab) in patients with 15 or more headache days a month (chronic migraine) and a recent history of acute migraine medication overuse.1 Also being presented at AHS are detailed results of STRIVE and ARISE, two Phase III studies of erenumab in people with 4 to 14 migraine days per month.2,3 Erenumab is the first fully human monoclonal antibody therapy specifically designed to target and block the Calcitonin Gene-Related Peptide (CGRP) receptor, believed to play a critical role in mediating the incapacitating pain of migraine. CGRP levels rise during a migraine attack and normalize when the attack goes away.4 "Migraine is one of the most debilitating neurological diseases, yet it is often misunderstood or ignored, despite devastating effects on patients' personal and professional life," said Vasant Narasimhan, Global Head Drug Development and Chief Medical Officer for Novartis.
